scholarly journals A STUDY ON STATUS OF URINARY HYDROXYPROLINE IN POST MENOPAUSAL WOMEN

2021 ◽  
Vol 9 (03) ◽  
pp. 136-146
Author(s):  
Lalrintlingi Sailo ◽  
Apurba Sarkar ◽  
Suresh Babu

Introduction: WHO and the Stages of Reproductive Aging Workshop have defined menopausal transition as the time of an increase in follicle-stimulating hormone and either increased variability in menstrual cycle length, two skipped menstrual cycles with 60 days or more of amenorrhea, or both. It concludes with the final menstrual period. Post-menopause begins at that time, although it is not recognized until after 12 months of amenorrhea. During menopause, women face various physiological, psychological, and biochemical changes. Laboratory medicine has given a new background to overcome the clinicianÂÂs diagnostic dilemma. Hydroxyproline is mainly found in collagen and accounts for 13% of total amino acid content and derived from proline by post-translational hydroxylation. Hydroxyproline is derived from another amino acid such as proline. Direct urinary assay of hydroxyproline to measure bone resorption have clinical applications as part of screening programs to assess the risk of osteoporotic fractures. Method: A total of seventy patients with regular medical follow-up records, The Patients were pre and post-menopausal women (35 each) recruited for this study. Patient details like body mass index, education, smoking, alcohol intake, dietary habits, and family history were considered before selecting the patients. Analytical Methods: Urinary Hydroxyproline and Urinary creatinine was estimated by Modified Neumann et al and Spectrophotometric JaffeÂÂs reaction respectively. Result: The study population consisted of 70 participants of premenopausal (n=35) and postmenopausal women (n=35), mean age of 38.11 ± 4.3 and 54.40 ± 4.6 respectively. The bone mineralization marker urinary total hydroxyproline was quantified in pre and post-menopausal women, which is 80.3 ± 75mg/L and 136 ± 103mg/L respectively. The urinary creatinine level in pre and post-menopausal women was 53.7 ± 14.2mg/dL and 37.0 ± 27.3 respectively. The hydroxyproline: creatinine ratio (HCR) was 41% to 69% against the normal reference interval in pre and post-menopausal women. Conclusion: The obtained normative data for the premenopausal woman population would be a new reference range in Indian sub-population or otherwise general population normative reference range commonly being used as a reference interval in all kind of pathophysiological disorders. Hence, the derived parameter confirmed that HCR is the most prognostic significant diagnostic marker in pre and post-menopausal patients.

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 415-415
Author(s):  
Mariah Jackson ◽  
Fang Niu ◽  
Lynette Smith ◽  
Laura Bilek ◽  
Nancy Waltman ◽  
...  

Abstract Objectives Determine the extent to which baseline protein and amino acid intake is independently associated with measures of baseline bone outcomes in a cohort of post-menopausal women. Methods This study was a secondary analysis of participants in the Heartland Osteoporosis Prevention Study (HOPS) randomized controlled trial evaluating the effect of different osteoporosis interventions on post-menopausal women in the Midwest. Diets were evaluated via a Harvard Willett Semi-quantitative Food Frequency Questionnaire (FFQ) at baseline. Dual energy x-ray absorptiometry (DXA) scans were used to collect bone mineral density (BMD) and trabecular bone score (TBS) measurements. Single and multivariate linear regression of total protein intake (g/d and g/kg/d), proline (g), and lysine (g) with BMD and TBS locations were conducted. Student T-tests were used to compare the bone outcome differences between groups with protein intake above and below 1.2g/kg. Results There were 249 participants available for analysis. Mean total protein intake was 82.7 g with 62% consuming < 1.2/kg/d. After adjustment, for every additional gram intake of protein, lysine and proline, Hip BMD increased (Protein: β = 0.0005, P = 0.047; Lysine: β = 0.006, P = 0.04; Proline: β = 0.008, P = 0.04). Whole body BMD and TBS-1 were significantly associated with proline intake (Whole body BMD: β = 0.008, P = 0.04; TBS-1: β = −0.007, P = 0.02). After adjustment, women who consumed protein above 1.2 g/kg, had a Hip BMD 0.03 g/cm2 higher than those who consume protein below 1.2 g/kg (β = 0.03, P = 0.046). Lumbar BMD, Total L1-L4 BMD, TBS-2, TBS-3, TBS-4, and Total TBS were not significantly associated with protein or amino acid intakes after adjustment of covariates. Conclusions Higher protein intakes were associated with higher Hip BMD. Proline may play a controversial role in bone outcomes. Future research should investigate the role of dietary factors on BMD vs TBS. Funding Sources The original research was funded by the National Institute of Nursing Research of the National Institutes of Health under award number R01NR015029. No additional funding was used for the secondary analysis.


1980 ◽  
Vol 59 (2) ◽  
pp. 137-142 ◽  
Author(s):  
A. Horsman ◽  
D. H. Marshall ◽  
B. E. C. Nordin ◽  
R. G. Crilly ◽  
M. Simpson

1. We have examined the relation between the rate of cortical bone loss and other measured variables in 108 women, untreated and on various therapies, observed for nearly 300 patient years. The majority of the subjects were post-menopausal women with various degrees of simple osteoporosis, but a few cases of hyperparathyroidism and other calcium disorders were included. 2. Calcium balance, bone resorption rate, urinary hydroxyproline and plasma alkaline phosphatase were shown to be related to the rate of bone loss; patients with the more negative balance or the higher values of the other variables had significantly higher rates of loss. The rate of bone loss was independent of the rate of bone formation.


1976 ◽  
Vol 35 (02) ◽  
pp. 403-414 ◽  
Author(s):  
Terence Davies ◽  
Gillian Fieldhouse ◽  
George P. McNicol

SummaryThe effects on the haemostatic mechanism of oestrogen therapy, given to prevent bone loss in post-menopausal women, have been investigated. Oestriol succinate was given orally to 10 women at a level of 2 mg/day for 1 month and for a further 3 months with incremental increase of 2 mg each month. 6 of the 10 women were subsequently treated with 25 μg/day orally of ethinyl oestradiol. Oestriol succinate therapy resulted in a small increase in the level of factor VII, a decrease in factor VIII concentration and increased sensitivity of platelets to aggregating agents. Ethinyl oestradiol treatment resulted in much more widespread changes with marked increases in coagulation factors VII, VIII, IX and X, decreased levels of antithrombin and dramatic increases in circulating plasminogen levels and euglobulin lysis activity. The data suggested that the nature of oestrogens employed therapeutically is important in determining the qualitative and quantitative effect of oestrogen therapy on components of the haemostatic mechanism.


2016 ◽  
Author(s):  
Antimo Moretti ◽  
Sire Alessandro de ◽  
Dario Calafiore ◽  
Raffaele Gimigliano ◽  
Francesca Gimigliano ◽  
...  

2016 ◽  
Author(s):  
Fernando Blanco-Rodriguez ◽  
Nicole Ellis-Infante ◽  
Victor Lopez-Rivas ◽  
Sherlin May-Kim ◽  
Charlotte Pickett ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document